Big Pharma Companies Team Up to Develop Once-Daily, Triple-Combination HIV Drug
Gilead Sciences Inc. (Foster City, CA, www.gilead.com) and Bristol-Myers Squibb Company (New York, NY, www.bms.com) have joined forces to bring a three-drug, once-daily treatment regimen for HIV to market. If approved, the treatment would be the first highly active antiretroviral therapy (HAART) for HIV that joins several drugs in a one-a-day tablet. Though HIV is a chronic, long-term treatable disease, pill burden and convenience have been a major challenge. Many HIV treatments require several pills to be taken several times per day, often resulting in missed doses. Says Norbert W. Bischofberger, PhD, executive vice-president of research and development at Gilead Sciences, "To come up with one pill that is essentially a triple-combination regimen is a big plus for patients. It makes the treatment much more convenient."
The new drug will combine Bristol-Myers Squibb's "Sustiva" (efavirenz) and Gilead's "Truvada" (emtricitabine and tenofovir disoproxil fumarate). Because all three drugs are on the market and proven safe for use, the main challenges will be formulation-related such as ensuring bioequivalence and stability for each component and also limiting interactions between the active ingredients.
A key concern for formulators is to develop a tablet that is small enough to swallow. If formulators simply combined the three existing formulations into a trilayer tablet, the drug would be 2.2 g. "You cannot make a pill more than 1.8 g. That's about the biggest size you can go so that people can still swallow it," explains Bischofberger. Limiting the volume and how many excipients are used in the formulations to use could be one way to create a single tablet that is less than 1.8 g.
Gilead and Bristol-Myers Squibb hope to file a new drug application in 2005 and to bring the drug to market in 2006.
-–Kaylynn Chiarello
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
WMFTS’ BioPure to Showcase Single-Use Bioclamp with Refined Manufacturing at INTERPHEX 2025
April 1st 2025With advanced manufacturing, BioPure’s BioClamp connector is manufactured to be 13% lighter than the previous model, resulting in a 26% reduction in carbon dioxide emissions across the full lifecycle of the product.